Physician profile
Timothy Monahan
NPI 1154321974
$11,773.54
in general payments reported to CMS, 2019-2025
28 companies · $2,206 in 2025
The $2,206 reported for 2025 was more than what 78% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,470 · 2020: $1,082 · 2021: $1,486 · 2022: $1,729 · 2023: $1,816 · 2024: $1,984 · 2025: $2,206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,647 · Education: $359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,646.63 |
| Education | $359.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,414.85 | 2019-2025 | |
| Ucb, INC. | $985.00 | 2019-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $951.44 | 2019-2025 | Tremfya, Stelara, Simponi |
| Genzyme Corporation | $820.04 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $800.55 | 2019-2025 | Dupixent, Libtayo |
| Amgen INC. | $717.06 | 2019-2025 | Otezla, Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $703.36 | 2019-2025 | Cabtreo, Jublia, Siliq |
| Novartis Pharmaceuticals Corporation | $680.07 | 2019-2025 | |
| Leo Pharma INC. | $573.00 | 2019-2025 | Adbry, Anzupgo |
| Pfizer INC. | $361.65 | 2019-2025 | |
| Lilly USA, LLC | $341.15 | 2019-2025 | Ebglyss, Olumiant, Taltz |
| E.R. Squibb & Sons, L.L.C. | $330.05 | 2022-2025 | Sotyktu |
| Celgene Corporation | $204.97 | 2019 | |
| Sun Pharmaceutical Industries INC. | $200.43 | 2021-2023 | Ilumya, Winlevi, Absorica Ld |
| Arcutis Biotherapeutics, INC. | $182.73 | 2023-2024 | Zoryve |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $126.21 | 2022-2025 | Nemluvio, Aklief |
| Incyte Corporation | $81.17 | 2023-2025 | Opzelura |
| Dermira, INC. | $43.84 | 2020-2021 | |
| Janssen Scientific Affairs, LLC | $40.35 | 2019 | |
| Genentech USA, INC. | $35.73 | 2019-2020 | |
| Dermavant Sciences, INC. | $34.33 | 2022-2023 | Vtama |
| Helsinn Therapeutics (U.S.), INC. | $27.37 | 2025 | Valchlor |
| Organon LLC | $22.75 | 2025 | |
| Aclaris Therapeutics, INC. | $21.50 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.41 | 2023 | Spevigo |
| Almirall LLC | $20.34 | 2019 | |
| Journey Medical Corporation | $18.29 | 2023 | |
| Vyne Pharmaceuticals INC. | $14.90 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Monahan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.